[1] Buchholz TA,Lehman CD,Harris JR,et al.Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer,a National Cancer Institute Conference.J Clin Oncol,2008,26(5):791-797.
[2] Skanberg J,Ahlman H,Benjegard SA,et al.Indium-111-octreotide scintigraphy,intraoperative ganana-detector localisation and somatostatin receptor expression in primary human breast cancer.Breast Cancer Res Treat,2002,74(8):101-111.
[3] 王少华,于泽平,李宁,等.生长抑素受体在乳腺癌组织中表达及其临床意义.实用临床医药杂志,2006,10(2):5-7.
[4] 王少华,于泽平,李刚,等.99mTc-Sandostatin生长抑素受体显像在原发性乳腺癌诊断中的意义.医学研究生学报,2005,18(12):1120-1121.
[5] 王佳琼,王自正,姚薇萱,等.99mTc-MIBI与99mTc-Octreotide生长抑素受体显像诊断乳腺癌的对比研究.中国医学影像学杂志,2006,14(2):91-93.
[6] Van Den Bosache B,Van Belle S,De Winter F,et al.Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTe-depreotide seintigraphy.J Nucl Med,2006,47(1):6-13.
[7] 孟召伟,董峰,谭建.乳腺癌的雌激素受体显像.国际放射医学核医学杂志,2007,31(3):157-159.
[8] Mankoff DA,Peterson LM,Tewson TJ,et al.[18F]fluoroestradiol radiation desimetry in human PET studies.J Nucl Med,2001,42(4):679-684.
[9] Linden HM,Stekhova SA,Link JM,et al.Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.J Clin Oncol,2006,24(18):2793-2799.
[10] Mortimer JE,Dehdashti F,Siegel BA,et al.Metabolic flare:Indicator of hormone responsiveness in advanced breast cancer.J Clin Oncol,2001,19(11):2797-2803.
[11] Zhang K,Aruva MR,Shantldy N,et al.Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP)receptor specific peptide analogues for PET imaging of breast cancer:In vitro/in vivo evaluation.Regul Pept,2007,144(1-3):91-100.
[12] Thakur ML,Aruva MR,Gariepy J,et al.PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog:comparison with 99mTc-VIP analog.J Nucl Med,2004,45(8):1381-1389.
[13] Moody TW,Jensen RT.Breast cancer VPAC1 receptors.Ann N Y Acad Sci,2006,1070:436-439.
[14] 雷炜,梁军,陈维刚,等.重组人白细胞介素-11治疗化疗所致血小板减少的临床观察.中华肿瘤杂志,2006,28(7):542-544.
[15] Morgan H,Tumber A,Hill PA.Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor.Int J Cancer,2004,109(5):653-660.
[16] Wang W,Ke S,Kwon S,et al.A new optical and nuclear duallabeled imaging agent targeting interteukin 11 receptor alphachain.Bioconjug Chem,2007,18(2):397-402.
[17] Singh B,Berry JA,Shoher A,et al.COX-2 induces IL-11 production in human breast cancer cells.J Surg Res,2006,131(2):267-275.
[18] Bennink RJ,vail Tienhoven G,Rijks U,et a1.In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer.J Nucl Med,2004,45(1):1-7.